多発性骨髄腫の世界市場（2025年～2032年）

世界の多発性骨髄腫の市場規模は、2024年に223億米ドルに達し、2032年には345億8,000万米ドルに達すると予測され、予測期間2024年～2032年のCAGRは5.6%で成長する見込みです。

多発性骨髄腫は、骨髄に存在する白血球の一種である形質細胞に発生するまれで攻撃的ながんです。この疾患は、異常な形質細胞の無秩序な増殖につながり、正常な血液細胞を押しのけてしまうため、骨損傷、腎機能障害、免疫力の低下など様々な合併症を引き起こします。

多発性骨髄腫市場は、疾患に対する意識の高まり、罹患率の上昇、革新的な治療法の開発などにより、大幅な成長を遂げています。新たな治療法や治療の組み合わせがパイプラインに加わるにつれて、市場は拡大し続けると予想されます。

市場力学：

促進要因と抑制要因

製品承認数の増加

製品承認数の増加は、利用可能な治療法の範囲を拡大し、患者に新たなソリューションを提供することで、多発性骨髄腫市場を大きく牽引しています。新たな治療法の研究開発が進むにつれ、製品承認数も増加しています。

化学療法や免疫療法などいくつかの革新的な治療法は、規制当局が定める安全性と有効性の基準を満たすことで承認を受けています。例えば、ジョンソン・エンド・ジョンソンは2024年4月、米国食品医薬品局（FDA）から、プロテアソーム阻害剤と免疫調節剤を含む少なくとも1つの前治療を受け、レナリドミドに抵抗性を示す再発または難治性の多発性骨髄腫の成人患者に対する治療薬であるCARVYKTI（ciltacabtagene autoleucel;cilta-cel）の承認を取得しました。今回の承認により、CARVYKTIは、多発性骨髄腫患者において、初回再発時からの使用が認められた最初で唯一のB細胞成熟抗原（BCMA）標的治療薬となります。

2024年9月、米国食品医薬品局（FDA）は、サルクリサ（イサツキシマブ）とボルテゾミブ、レナリドミド、デキサメタゾン（VRd）の併用療法を、自家幹細胞移植（ASCT）が不適格な新規診断の多発性骨髄腫（NDMM）成人患者に対する一次治療として承認しました。サルクリサは、標準的なVRdレジメンと併用する初めての抗CD38療法であり、移植の候補とならないNDMM患者において、VRd単独療法と比較して疾患進行または死亡のリスクを40％有意に減少させます。

高額な治療費

多発性骨髄腫の治療費が高額であることが、多発性骨髄腫市場の成長を妨げると予想されます。治療費が高いため、治療を受ける人が減ると予想されます。例えば、2022年の米国国立衛生研究所によると、多発性骨髄腫関連の医療費（患者一人当たり67万561米ドル）は、全原因医療費の平均88.5%に寄与しており、MM関連の医療費の大部分（67.2%）は薬剤費と輸液費（患者一人当たり45万952米ドル）に起因しています。このように、治療費が高額になるため、経済的な理由で治療を受けられない患者も多く、市場の成長に悪影響を及ぼす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 製品承認数の増加
  • 抑制要因
    • 高額な治療費
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• くすぶり型（無症候性）多発性骨髄腫
• 活動性（有症候性）多発性骨髄腫

第7章 治療別

• 化学療法
• 免疫療法
• 放射線
• 幹細胞移植
• 標的療法

第8章 エンドユーザー別

• 病院
• がんセンター
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Amgen Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 実績および予測の製品販売
    • 製品販売量
  • 財務概要
    • 企業収益
    • 地域別収益シェア
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Sanofi
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• ONO PHARMACEUTICAL CO., LTD.
• Pfizer Inc.
• Karyopharm
• Amneal Pharmaceuticals LLC.
• GSK plc
  • パイプライン製品の説明
  • 製品の主要業績評価指標（KPI）
  • 主な活動
  • 市場参入のタイムライン
  • 製品普及率
  • 売上推定と予測
• Takeda Pharmaceutical Company Limited
• Poseida Therapeutics
• Regeneron Pharmaceuticals, Inc.
• Genentech, Inc.

第12章 付録

The global multiple myeloma market reached US$ 22.3 billion in 2024 and is expected to reach US$ 34.58 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2024-2032.

Multiple myeloma is a rare and aggressive cancer that originates in the plasma cells, a type of white blood cell found in the bone marrow. This condition leads to the uncontrolled growth of abnormal plasma cells, which crowd out normal blood cells, resulting in various complications such as bone damage, kidney dysfunction, and weakened immunity.

The multiple myeloma treatment market has witnessed substantial growth, driven by increasing disease awareness, rising incidence rates, and the development of innovative therapies. The market is expected to continue expanding as new therapies and treatment combinations enter the pipeline.

Market Dynamics: Drivers & Restraints

Rising number of product approvals

The rising number of product approvals is significantly driving the multiple myeloma treatment market by expanding the range of available therapies and offering new solutions for patients. With the rising research and development of new solutions there has been growing products approvals.

Several innovative solutions such as chemotherapy, immunotherapy treatments are receiving approvals by meeting the safety and efficacy standards set by the regulatory bodies. For instance, in April 2024, Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for CARVYKTI (ciltacabtagene autoleucel; cilta-cel), a treatment for adult patients with relapsed or refractory multiple myeloma who have undergone at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. This approval makes CARVYKTI the first and only B-cell maturation antigen (BCMA)-targeted therapy authorized for use in multiple myeloma patients as early as their first relapse.

In September 2024, the U.S. Food and Drug Administration (FDA) approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment for adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). Sarclisa is the first anti-CD38 therapy combined with the standard VRd regimen to significantly reduce the risk of disease progression or death by 40% compared to VRd alone in patients with NDMM who are not candidates for transplant.

High Cost of Treatment

The high cost of multiple myeloma treatment is expected to hinder the multiple myeloma market growth. The high costs of the treatment are expected to reduce the number of individuals from undergoing treatment. For instance according to the National Institute of Health in 2022, multiple myeloma related healthcare costs (US$670,561 per patient) contributed on average 88.5% to the total all-cause healthcare costs; the majority (67.2%) of MM-related healthcare costs were attributed to drug and infusion costs (US$450,952 per patient). Thus, the expensiveness of treatment could not be afforded by the individuals with financial barriers which could impact the market growth negatively.

Segment Analysis

The global multiple myeloma market is segmented based on type, treatment, end-user, and region.

Type:

Immunotherapy segment is expected to dominate the global multiple myeloma market share

Immunotherapy segment holds a major portion of the multiple myeloma market share. Additionally, the increased investment in research and development by pharmaceutical companies is fostering innovation in this area. As more advanced therapies enter the market, they are expected to attract significant attention from healthcare providers and patients

Several ongoing research and developments for multiple myeloma and the increasing preference by the patients are expected to hold the segment in the dominant position. For instance, in August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced received the U.S. Food and Drug Administration (FDA) accelerated approval of TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Geographical Analysis

North America is expected to hold a significant position in the global multiple myeloma market share

North America is expected to hold a dominant position in the global multiple myeloma market. This is primarily driven by the increasing occurrence of multiple myeloma, rising approvals of the products in the region and the presence of large number of market players in the region.

The companies in the region are actively developing novel drugs, which enhances competition and drives the region's market growth. Market players are increasingly receiving approvals for the innovative solutions that are being developed. For instance, in September 2024, Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited ("Shilpa") received the U.S. Food and Drug Administration (FDA) approval of BORUZU. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. BORUZU (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.

In March 2024, Poseida Therapeutics, Inc. received Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM). Thus, the above factors are expected to drive the region's market growth.

Competitive Landscape

The major global players in the multiple myeloma market include Amgen Inc., Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, ONO PHARMACEUTICAL CO., LTD., Pfizer Inc., Karyopharm and Amneal Pharmaceuticals LLC. among others.

Key Developments

• In April 2024, Bristol Myers Squibb ("BMS") and 2seventy bio, Inc. received FDA approval for ABECMA (idecabtagene vicleucel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.
• In March 2024, Kite, a Gilead Company and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder.
• In March 2023, Natco Pharma Ltd launched additional strengths for its generic lenalidomide capsules used in the treatment of multiple myeloma, in the US. The company has launched 2.5 mg, and 20 mg strengths of the generic version of Revlimid (lenalidomide capsules) through its marketing partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Multiple Myeloma Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising number of product approvals
  • 4.1.2. Restraints
    • 4.1.2.1. High costs of treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Smoldering (Indolent) Multiple Myeloma*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Active (Symptomatic) Multiple Myeloma

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Chemotherapy*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Immunotherapy
• 7.4. Radiation
• 7.5. Stem Cell Transplant
• 7.6. Targeted Therapy

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cancer Centers
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. Amgen Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Sanofi
• 11.3. Novartis AG
• 11.4. Teva Pharmaceutical Industries Ltd.
• 11.5. Johnson & Johnson Services, Inc.
• 11.6. Bristol-Myers Squibb Company
• 11.7. ONO PHARMACEUTICAL CO., LTD.
• 11.8. Pfizer Inc.
• 11.9. Karyopharm
• 11.10. Amneal Pharmaceuticals LLC.
• Similar data will be provided for each market player.

Emerging Market Players

• 11.11. GSK plc*
  • 11.11.1. Pipeline Products Description
  • 11.11.2. Product Key Performance Indicators (KPIs)
  • 11.11.3. Key Activities
  • 11.11.4. Market Entry Timelines
  • 11.11.5. Product Penetration Rate
  • 11.11.6. Sales Estimation and Projections
• 11.12. Takeda Pharmaceutical Company Limited
• 11.13. Poseida Therapeutics
• 11.14. Regeneron Pharmaceuticals, Inc.
• 11.15. Genentech, Inc.
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us